BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gisbert JP, González L, Calvet X, García N, López T, Roqué M, Gabriel R, Pajares JM. Proton pump inhibitor, clarithromycin and either amoxycillin or nitroimidazole: a meta-analysis of eradication of Helicobacter pylori. Aliment Pharmacol Ther. 2000;14:1319-1328. [PMID: 11012477 DOI: 10.1046/j.1365-2036.2000.00844.x] [Cited by in Crossref: 117] [Cited by in F6Publishing: 115] [Article Influence: 5.3] [Reference Citation Analysis]
Number Citing Articles
1 Gisbert JP, Pajares R, Pajares JM. Evolution of Helicobacter pylori Therapy from a Meta-analytical Perspective. Helicobacter 2007;12:50-8. [DOI: 10.1111/j.1523-5378.2007.00576.x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 53] [Article Influence: 3.4] [Reference Citation Analysis]
2 Peitz U, Sulliga M, Wolle K, Leodolter A, Von Arnim U, Kahl S, Stolte M, Börsch G, Labenz J, Malfertheiner P. High rate of post-therapeutic resistance after failure of macrolide-nitroimidazole triple therapy to cure Helicobacter pylori infection: impact of two second-line therapies in a randomized study. Aliment Pharmacol Ther. 2002;16:315-324. [PMID: 11860415 DOI: 10.1046/j.1365-2036.2002.01173.x] [Cited by in Crossref: 73] [Cited by in F6Publishing: 71] [Article Influence: 3.7] [Reference Citation Analysis]
3 Sharara AI, Chaar HF, Aoun E, Abdul-Baki H, Araj GF, Kanj SS. Efficacy and safety of rabeprazole, amoxicillin, and gatifloxacin after treatment failure of initial Helicobacter pylori eradication. Helicobacter. 2006;11:231-236. [PMID: 16882325 DOI: 10.1111/j.1523-5378.2006.00416.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.3] [Reference Citation Analysis]
4 Mansour-Ghanaei F, Joukar F, Naghipour MR, Forouhari A, Seyed Saadat SM. Seven-day quintuple regimen as a rescue therapy for Helicobacter pylori eradication. World J Gastroenterol 2015; 21(2): 661-666 [PMID: 25593496 DOI: 10.3748/wjg.v21.i2.661] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
5 Treiber G, Malfertheiner P, Klotz U. Treatment and dosing of Helicobacter pylori infection: when pharmacology meets clinic. Expert Opin Pharmacother 2007;8:329-50. [PMID: 17266468 DOI: 10.1517/14656566.8.3.329] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
6 Nijevitch AA, Sataev VU, Akhmadeyeva EN, Arsamastsev AG. Nifuratel-containing initial anti-Helicobacter pylori triple therapy in children. Helicobacter. 2007;12:132-135. [PMID: 17309749 DOI: 10.1111/j.1523-5378.2007.00482.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
7 Kim SY, Chung JW. Best Helicobacter pylori Eradication Strategy in the Era of Antibiotic Resistance. Antibiotics (Basel) 2020;9:E436. [PMID: 32717826 DOI: 10.3390/antibiotics9080436] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
8 Kositchaiwat C, Ovartlarnporn B, Kachintorn U, Atisook K. Low and high doses of rabeprazole vs. omeprazole for cure of Helicobacter pylori infection. Aliment Pharmacol Ther. 2003;18:1017-1021. [PMID: 14616168 DOI: 10.1046/j.1365-2036.2003.01701.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
9 Kim SY, Choi DJ, Chung JW. Antibiotic treatment for Helicobacter pylori: Is the end coming? World J Gastrointest Pharmacol Ther 2015; 6(4): 183-198 [PMID: 26558152 DOI: 10.4292/wjgpt.v6.i4.183] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 30] [Article Influence: 5.1] [Reference Citation Analysis]
10 Gisbert JP, Pajares JM. Treatment of Helicobacter pylori infection: The past and the future. European Journal of Internal Medicine 2010;21:357-9. [DOI: 10.1016/j.ejim.2010.07.009] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
11 Mansour-Ghanaei F, Samadi A, Joukar F, Tirgar Fakheri H, Hassanipour S, Ashoobi MT, Soltanipour S, Alizadeh A, Rezamand G, Fathalipour M. Efficacy and tolerability of fourteen-day sequential quadruple regimen: pantoprazole, bismuth, amoxicillin, metronidazole and or furazolidone as first-line therapy for eradication of Helicobacter pylori: a randomized, double-blind clinical trial. EXCLI J 2019;18:644-52. [PMID: 31611747 DOI: 10.17179/excli2019-1613] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Gisbert JP, Fernández-Bermejo M, Molina-Infante J, Pérez-Gallardo B, Prieto-Bermejo AB, Mateos-Rodríguez JM, Robledo-Andrés P, González-García G. First-line triple therapy with levofloxacin for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2007;26:495-500. [PMID: 17635384 DOI: 10.1111/j.1365-2036.2007.03384.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 36] [Article Influence: 2.1] [Reference Citation Analysis]
13 Katelaris PH. Helicobacter pylori: Why are eradication results so variable? J Gastroenterol Hepatol 2004;19:606-9. [DOI: 10.1111/j.1440-1746.2004.03453.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
14 Sharara AI. Rabeprazole: the role of proton pump inhibitors in Helicobacter pylori eradication. Expert Review of Anti-infective Therapy 2014;3:863-70. [DOI: 10.1586/14787210.3.6.863] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
15 Sue S, Suzuki N, Shibata W, Sasaki T, Yamada H, Kaneko H, Tamura T, Ishii T, Kondo M, Maeda S. First-Line Helicobacter pylori Eradication with Vonoprazan, Clarithromycin, and Metronidazole in Patients Allergic to Penicillin. Gastroenterol Res Pract 2017;2017:2019802. [PMID: 29181022 DOI: 10.1155/2017/2019802] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
16 Nguyen CT, Davis KA, Nisly SA, Li J. Treatment of Helicobacter pylori in Special Patient Populations. Pharmacotherapy 2019;39:1012-22. [DOI: 10.1002/phar.2318] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
17 Silva FM, Eisig JN, Teixeira AC, Barbuti RC, Navarro-Rodriguez T, Mattar R. Short-term triple therapy with azithromycin for Helicobacter pylori eradication: low cost, high compliance, but low efficacy. BMC Gastroenterol 2008;8:20. [PMID: 18510773 DOI: 10.1186/1471-230X-8-20] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
18 Nyssen OP, McNicholl AG, Gisbert JP. Meta-analysis of three-in-one single capsule bismuth-containing quadruple therapy for the eradication of Helicobacter pylori. Helicobacter. 2019;24:e12570. [PMID: 30767339 DOI: 10.1111/hel.12570] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 9.7] [Reference Citation Analysis]
19 Abd-Elsalam S, Kobtan A, El-Kalla F, Elkhalawany W, Nawasany SE, Saif SA, Yousef M, Ali LA, Soliman S, Mansour L, Habba E, Soliman H, Rizk F, Shehata MA. A 2-week Nitazoxanide-based quadruple treatment as a rescue therapy for Helicobacter pylori eradication: A single center experience. Medicine (Baltimore) 2016;95:e3879. [PMID: 27310977 DOI: 10.1097/MD.0000000000003879] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 2.6] [Reference Citation Analysis]
20 Egli K, Wagner K, Keller PM, Risch L, Risch M, Bodmer T. Comparison of the Diagnostic Performance of qPCR, Sanger Sequencing, and Whole-Genome Sequencing in Determining Clarithromycin and Levofloxacin Resistance in Helicobacter pylori. Front Cell Infect Microbiol 2020;10:596371. [PMID: 33392106 DOI: 10.3389/fcimb.2020.596371] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
21 Buzás GM, Józan J. Nitrofuran-based regimens for the eradication of Helicobacter pylori infection. J Gastroenterol Hepatol. 2007;22:1571-1581. [PMID: 17845685 DOI: 10.1111/j.1440-1746.2007.05082.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 2.1] [Reference Citation Analysis]
22 Ramos-Soriano AG, Black J. Nitazoxanide Use as Part of an Empiric Multi-Drug Regimen in Treating Children with Suspected Helicobacter pylori Infection. Case Rep Gastroenterol 2015;9:36-42. [PMID: 25759631 DOI: 10.1159/000375116] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
23 Katelaris PH, Forbes GM, Talley NJ, Crotty B. A randomized comparison of quadruple and triple therapies for Helicobacter pylori eradication: The QUADRATE Study. Gastroenterology. 2002;123:1763-1769. [PMID: 12454831 DOI: 10.1053/gast.2002.37051] [Cited by in Crossref: 110] [Cited by in F6Publishing: 108] [Article Influence: 5.5] [Reference Citation Analysis]
24 Poon SK, Chang CS, Su J, Lai CH, Yang CC, Chen GH, Wang WC. Primary resistance to antibiotics and its clinical impact on the efficacy of Helicobacter pylori lansoprazole-based triple therapies. Aliment Pharmacol Ther. 2002;16:291-296. [PMID: 11860412 DOI: 10.1046/j.1365-2036.2002.01184.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 2.1] [Reference Citation Analysis]
25 Kim CG, Song HJ, Kook MC, Hong EK, Park S, Lee JY, Lee JH, Ryu KW, Kim YW, Bae JM. Preoperative versus postoperative Helicobacter pylori eradication therapy in gastric cancer patients: a randomized trial. Am J Gastroenterol. 2008;103:48-54. [PMID: 17714557 DOI: 10.1111/j.1572-0241.2007.01482.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
26 Di Mario F, Cavallaro LG, Scarpignato C. ‘Rescue’ therapies for the management of Helicobacter pylori infection. Dig Dis. 2006;24:113-130. [PMID: 16699270 DOI: 10.1159/000090315] [Cited by in Crossref: 37] [Cited by in F6Publishing: 42] [Article Influence: 2.3] [Reference Citation Analysis]
27 Gupta N, Maurya S, Verma H, Verma VK. Unraveling the factors and mechanism involved in persistence: Host-pathogen interactions in Helicobacter pylori. J Cell Biochem. 2019;120:18572-18587. [PMID: 31237031 DOI: 10.1002/jcb.29201] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
28 Ergin A, Çiyiltepe H, Karip AB, Fersahoğlu MM, Bulut NE, Çakmak A, Topaloğlu B, Bilgili AC, Somay A, Taşdelen İ, Akyüz Ü, Memişoğlu K. The Effect of Helicobacter pylori Eradication on Gastric Wall Thickness in Patients Undergoing Laparoscopic Sleeve Gastrectomy. Obes Surg 2021;31:4024-32. [PMID: 34075550 DOI: 10.1007/s11695-021-05513-8] [Reference Citation Analysis]
29 Pohl D, Keller PM, Bordier V, Wagner K. Review of current diagnostic methods and advances in Helicobacter pylori diagnostics in the era of next generation sequencing. World J Gastroenterol 2019; 25(32): 4629-4660 [PMID: 31528091 DOI: 10.3748/wjg.v25.i32.4629] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 21] [Article Influence: 9.3] [Reference Citation Analysis]
30 Feu F, Brullet E, Calvet X, Fernández-llamazares J, Guardiola J, Moreno P, Panadès A, Saló J, Saperas E, Villanueva C, Planas R. Recomendaciones para el diagnóstico y el tratamiento de la hemorragia digestiva alta aguda no varicosa. Gastroenterología y Hepatología 2003;26:70-85. [DOI: 10.1016/s0210-5705(03)79046-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
31 Khan S, Sharaf M, Ahmed I, Khan TU, Shabana S, Arif M, Kazmi SSUH, Liu C. Potential utility of nano-based treatment approaches to address the risk of Helicobacter pylori. Expert Rev Anti Infect Ther 2021;:1-18. [PMID: 34658307 DOI: 10.1080/14787210.2022.1990041] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Yoon JH, Baik GH, Kim YS, Suk KT, Shin WG, Kim KH, Kim KO, Park CH, Baik IH, Jang HJ. Comparison of the Eradication Rate between 1- and 2-Week Bismuth-Containing Quadruple Rescue Therapies for Helicobacter pylori Eradication. Gut Liver. 2012;6:434-439. [PMID: 23170146 DOI: 10.5009/gnl.2012.6.4.434] [Cited by in Crossref: 22] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
33 Gisbert JP, Pérez-Aisa A, Castro-Fernández M, Barrio J, Rodrigo L, Cosme A, Gisbert JL, Marcos S, Moreno-Otero R. Helicobacter pylori first-line treatment and rescue option containing levofloxacin in patients allergic to penicillin. Dig Liver Dis. 2010;42:287-290. [PMID: 19632166 DOI: 10.1016/j.dld.2009.06.007] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 2.8] [Reference Citation Analysis]
34 Huang J, Lam SK, Malfertheiner P, Hunt RH. Has education about Helicobacter pylori infection been effective Worldwide survey of primary care physicians. J Gastroenterol Hepatol. 2003;18:512-520. [PMID: 12702042 DOI: 10.1046/j.1440-1746.2003.03017.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
35 Gisbert JP, McNicholl AG. Optimization strategies aimed to increase the efficacy of H. pylori eradication therapies. Helicobacter. 2017;22. [PMID: 28464347 DOI: 10.1111/hel.12392] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 7.4] [Reference Citation Analysis]
36 Gisbert JP. Tratamientos de rescate ante el fracaso erradicador de Helicobacter pylori. Gastroenterología y Hepatología 2011;34:89-99. [DOI: 10.1016/j.gastrohep.2010.10.013] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
37 Makobongo MO, Kovachi T, Gancz H, Mor A, Merrell DS. In vitro antibacterial activity of acyl-lysyl oligomers against Helicobacter pylori. Antimicrob Agents Chemother 2009;53:4231-9. [PMID: 19620333 DOI: 10.1128/AAC.00510-09] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
38 Vallve M, Vergara M, Gisbert JP, Calvet X. Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis. Aliment Pharmacol Ther. 2002;16:1149-1156. [PMID: 12030958 DOI: 10.1046/j.1365-2036.2002.01270.x] [Cited by in Crossref: 87] [Cited by in F6Publishing: 79] [Article Influence: 4.4] [Reference Citation Analysis]
39 Gisbert JP, Marcos S, Gisbert JL, Pajares JM. High efficacy of ranitidine bismuth citrate, amoxicillin, clarithromycin and metronidazole twice daily for only five days in Helicobacter pylori Eradication. Helicobacter. 2001;6:157-162. [PMID: 11422472 DOI: 10.1046/j.1523-5378.2001.00023.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 0.7] [Reference Citation Analysis]
40 Gisbert JP. Second-line rescue therapy of helicobacter pylori infection. Therap Adv Gastroenterol. 2009;2:331-356. [PMID: 21180581 DOI: 10.1177/1756283x09347109] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
41 Gisbert JP, Barrio J, Modolell I, Molina-Infante J, Aisa AP, Castro-Fernández M, Rodrigo L, Cosme A, Gisbert JL, Fernández-Bermejo M, Marcos S, Marín AC, McNicholl AG. Helicobacter pylori first-line and rescue treatments in the presence of penicillin allergy. Dig Dis Sci 2015;60:458-64. [PMID: 25236423 DOI: 10.1007/s10620-014-3365-2] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]
42 Morgner A, Labenz J, Miehlke S. Effective regimens for the treatment of Helicobacter pylori infection. Expert Opin Investig Drugs 2006;15:995-1016. [PMID: 16916269 DOI: 10.1517/13543784.15.9.995] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
43 Kabakambira JD, Hategeka C, Page C, Ntirenganya C, Dusabejambo V, Ndoli J, Ngabonziza F, Hale D, Bayingana C, Walker T. Efficacy of Helicobacter pylori eradication regimens in Rwanda: A randomized controlled trial. BMC Gastroenterol. 2018;18:134. [PMID: 30165823 DOI: 10.1186/s12876-018-0863-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
44 Storskrubb T, Aro P, Ronkainen J, Wreiber K, Nyhlin H, Bolling-Sternevald E, Talley NJ, Engstrand L, Agréus L. Antimicrobial susceptibility of Helicobacter pylori strains in a random adult Swedish population. Helicobacter. 2006;11:224-230. [PMID: 16882324 DOI: 10.1111/j.1523-5378.2006.00414.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 35] [Article Influence: 1.8] [Reference Citation Analysis]
45 Peura DA, Crowe SE. Helicobacter pylori. Sleisenger and Fordtran's Gastrointestinal and Liver Disease. Elsevier; 2010. pp. 833-843.e4. [DOI: 10.1016/b978-1-4160-6189-2.00050-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
46 Gisbert JP. “Rescue” regimens after Helicobacter pylori treatment failure. World J Gastroenterol 2008; 14(35): 5385-5402 [PMID: 18803350 DOI: 10.3748/wjg.14.5385] [Cited by in CrossRef: 79] [Cited by in F6Publishing: 77] [Article Influence: 5.6] [Reference Citation Analysis]
47 Gisbert JP. Rescue Therapy for Helicobacter pylori Infection 2012. Gastroenterol Res Pract. 2012;2012:974594. [PMID: 22536225 DOI: 10.1155/2012/974594] [Cited by in Crossref: 19] [Cited by in F6Publishing: 28] [Article Influence: 1.9] [Reference Citation Analysis]
48 Bochenek WJ, Peters S, Fraga PD, Wang W, Mack ME, Osato MS, El-Zimaity HM, Davis KD, Graham DY. Eradication of Helicobacter pylori by 7-day triple-therapy regimens combining pantoprazole with clarithromycin, metronidazole, or amoxicillin in patients with peptic ulcer disease: results of two double-blind, randomized studies. Helicobacter. 2003;8:626-642. [PMID: 14632678 DOI: 10.1111/j.1523-5378.2003.00179.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 1.7] [Reference Citation Analysis]
49 Marin AC, McNicholl AG, Gisbert JP. A review of rescue regimens after clarithromycin-containing triple therapy failure (for Helicobacter pylori eradication). Expert Opin Pharmacother. 2013;14:843-861. [PMID: 23537368 DOI: 10.1517/14656566.2013.782286] [Cited by in Crossref: 55] [Cited by in F6Publishing: 42] [Article Influence: 6.1] [Reference Citation Analysis]
50 Gisbert JP, Calvet X, Ferrándiz J, Mascort J, Alonso-Coello P, Marzo M; Sociedad Española de Medicina de Familia y Comunitaria. [Clinical practice guideline on the management of patients with dyspepsia. Update 2012]. Gastroenterol Hepatol 2012;35:725.e1-38. [PMID: 23186826 DOI: 10.1016/j.gastrohep.2012.05.002] [Cited by in Crossref: 4] [Article Influence: 0.4] [Reference Citation Analysis]
51 Zhou Y, Taylor B, Smith TJ, Liu Z, Clench M, Davies NW, Rainsford KD. A novel compound from celery seed with a bactericidal effect against Helicobacter pylori. Journal of Pharmacy and Pharmacology 2009;61:1067-77. [DOI: 10.1211/jpp.61.08.0011] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
52 Mamori S, Higashida A, Kawara F, Ohnishi K, Takeda A, Senda E, Ashida C, Yamada H. Age-dependent eradication of Helicobacter pylori in Japanese patients. World J Gastroenterol 2010; 16(33): 4176-4179 [PMID: 20806435 DOI: 10.3748/wjg.v16.i33.4176] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
53 Buzás GM. First-line eradication of Helicobacter pylori: Are the standard triple therapies obsolete? A different perspective. World J Gastroenterol 2010; 16(31): 3865-3870 [PMID: 20712046 DOI: 10.3748/wjg.v16.i31.3865] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
54 Farup PG, Lange OJ, Tholfsen J, Høeg V, Wetterhus S. The Effect of Helicobacter pylori Retreatment With Ranitidine Bismuth Citrate, Clarithromycin, and Metronidazole Depends on the First-Line Therapy: . Journal of Clinical Gastroenterology 2002;35:379-82. [DOI: 10.1097/00004836-200211000-00004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
55 Shah A, Javid G, Zargar SA, Teli F, Khan BA, Yattoo GN, Gulzar GM, Sodhi JS, Khan MA, Shoukat A. Safety and efficacy of 1-week levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori-related peptic ulcer disease in Kashmir, India. Indian J Gastroenterol. 2013;32:32-36. [PMID: 23224792 DOI: 10.1007/s12664-012-0285-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
56 Gisbert JP, Pajares JM. Review article: Helicobacter pylori “rescue” regimen when proton pump inhibitor-based triple therapies fail. Aliment Pharmacol Ther. 2002;16:1047-1057. [PMID: 12030945 DOI: 10.1046/j.1365-2036.2002.01276.x] [Cited by in Crossref: 166] [Cited by in F6Publishing: 152] [Article Influence: 8.3] [Reference Citation Analysis]
57 Xia HH, Yu Wong BC, Talley NJ, Lam SK. Helicobacter pylori infection - current treatment practice. Expert Opinion on Pharmacotherapy 2005;2:253-66. [DOI: 10.1517/14656566.2.2.253] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
58 Suzuki T, Matsuo K, Ito H, Sawaki A, Hirose K, Wakai K, Sato S, Nakamura T, Yamao K, Ueda R. Smoking increases the treatment failure for Helicobacter pylori eradication. Am J Med. 2006;119:217-224. [PMID: 16490464 DOI: 10.1016/j.amjmed.2005.10.003] [Cited by in Crossref: 105] [Cited by in F6Publishing: 97] [Article Influence: 6.6] [Reference Citation Analysis]
59 Cortés P, Nelson AD, Bi Y, Stancampiano FF, Murray LP, Pujalte GGA, Gomez V, Harris DM. Treatment Approach of Refractory Helicobacter pylori Infection: A Comprehensive Review. J Prim Care Community Health 2021;12:21501327211014087. [PMID: 33949229 DOI: 10.1177/21501327211014087] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
60 Fakheri H, Bakhshi Z, Bari Z, Alhooei S. Effects of Clarithromycin-Containing Quadruple Therapy on Helicobacter Pylori Eradication after Nitroimidazole-Containing Quadruple Therapy Failure. Middle East J Dig Dis 2016;8:51-6. [PMID: 26933482 DOI: 10.15171/mejdd.2016.07] [Cited by in Crossref: 4] [Article Influence: 0.7] [Reference Citation Analysis]
61 Ghobadi E, Ghanbarimasir Z, Emami S. A review on the structures and biological activities of anti-Helicobacter pylori agents. Eur J Med Chem 2021;223:113669. [PMID: 34218084 DOI: 10.1016/j.ejmech.2021.113669] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
62 Huang JQ, Zheng GF, Irvine EJ, Karlberg J. Assessing heterogeneity in meta-analyses of Helicobacter pylori infection-related clinical studies: a critical appraisal. Chin J Dig Dis 2004;5:126-33. [PMID: 15612249 DOI: 10.1111/j.1443-9573.2004.00169.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
63 Choi IJ, Jung HC, Choi KW, Kim JH, Ahn DS, Yang US, Rew JS, Lee SI, Rhee JC, Chung IS, Chung JM, Hong WS. Efficacy of low-dose clarithromycin triple therapy and tinidazole-containing triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther 2002;16:145-51. [PMID: 11856089 DOI: 10.1046/j.1365-2036.2002.01130.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
64 Gisbert JP, Gisbert JL, Marcos S, Jimenez-Alonso I, Moreno-Otero R, Pajares JM. Empirical rescue therapy after Helicobacter pylori treatment failure: a 10-year single-centre study of 500 patients. Aliment Pharmacol Ther. 2008;27:346-354. [PMID: 17999716 DOI: 10.1111/j.1365-2036.2007.03573.x] [Cited by in Crossref: 60] [Cited by in F6Publishing: 61] [Article Influence: 4.0] [Reference Citation Analysis]
65 Malfertheiner P, Mégraud F, O’Morain C, Hungin AP, Jones R, Axon A, Graham DY, Tytgat G. Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther. 2002;16:167-180. [PMID: 11860399 DOI: 10.1046/j.1365-2036.2002.01169.x] [Cited by in Crossref: 826] [Cited by in F6Publishing: 809] [Article Influence: 41.3] [Reference Citation Analysis]
66 Mascellino MT, Porowska B, De Angelis M, Oliva A. Antibiotic susceptibility, heteroresistance, and updated treatment strategies in Helicobacter pylori infection. Drug Des Devel Ther 2017;11:2209-20. [PMID: 28814829 DOI: 10.2147/DDDT.S136240] [Cited by in Crossref: 19] [Cited by in F6Publishing: 7] [Article Influence: 3.8] [Reference Citation Analysis]
67 Huang JQ, Zheng GF, Hunt RH, Wong WM, Lam SK, Karlberg J, Wong BCY. Do patients with non-ulcer dyspepsia respond differently to Helicobacter pylori eradication treatments from those with peptic ulcer disease? A systematic review. World J Gastroenterol 2005; 11(18): 2726-2732 [PMID: 15884111 DOI: 10.3748/wjg.v11.i18.2726] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
68 Song M, Ang TL. Second and third line treatment options for Helicobacter pylori eradication. World J Gastroenterol 2014; 20(6): 1517-1528 [PMID: 24587627 DOI: 10.3748/wjg.v20.i6.1517] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
69 Gisbert JP, Calvet X, Ferrándiz J, Mascort J, Alonso-Coello P, Marzo M; Asociación Española de Gastroenterología., Sociedad Española de Medicina de Familia y Comunitaria., Centro Cochrane Iberoamericano. [Clinical practice guideline on the management of patients with dyspepsia. Update 2012]. Aten Primaria 2012;44:727.e1-727.e38. [PMID: 23036729 DOI: 10.1016/j.aprim.2012.05.003] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
70 Rodgers C, van Zanten SV. A meta-analysis of the success rate of Helicobacter pylori therapy in Canada. Can J Gastroenterol 2007;21:295-300. [PMID: 17505565 DOI: 10.1155/2007/419784] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 0.9] [Reference Citation Analysis]
71 Ulmer H, Beckerling A, Gatz G. Recent Use of Proton Pump Inhibitor-Based Triple Therapies for the Eradication of H. pylori: A Broad Data Review. Helicobacter 2003;8:95-104. [DOI: 10.1046/j.1523-5378.2003.00129.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 1.9] [Reference Citation Analysis]
72 Kwok A, Lam T, Katelaris P, Leong RW. Helicobacter pylori eradication therapy: indications, efficacy and safety. Expert Opin Drug Saf 2008;7:271-81. [PMID: 18462185 DOI: 10.1517/14740338.7.3.271] [Cited by in Crossref: 21] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
73 Vaira U, Gatta L, Ricci C, D'Anna L, Iglioli MM. Helicobacter pylori: diseases, tests and treatment. Dig Liver Dis 2001;33:788-94. [PMID: 11838615 DOI: 10.1016/s1590-8658(01)80697-6] [Cited by in Crossref: 23] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
74 Sierra F, Forero JD, Rey M. [Ideal treatment for Helicobacter pylori: a systematic review]. Rev Gastroenterol Mex 2014;79:28-49. [PMID: 24365458 DOI: 10.1016/j.rgmx.2013.03.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
75 Marcus EA, Sachs G, Scott DR. Eradication of Helicobacter pylori Infection. Curr Gastroenterol Rep 2016;18:33. [PMID: 27177639 DOI: 10.1007/s11894-016-0509-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
76 Gisbert JP, Alcedo J, Amador J, Bujanda L, Calvet X, Castro-Fernández M, Fernández-Salazar L, Gené E, Lanas Á, Lucendo AJ, Molina-Infante J, Nyssen OP, Pérez-Aisa A, Puig I. V Spanish Consensus Conference on Helicobacter pylori infection treatment. Gastroenterol Hepatol 2021:S0210-5705(21)00229-6. [PMID: 34629204 DOI: 10.1016/j.gastrohep.2021.07.011] [Reference Citation Analysis]
77 Zagari RM, Bianchi-Porro G, Fiocca R, Gasbarrini G, Roda E, Bazzoli F. Comparison of 1 and 2 weeks of omeprazole, amoxicillin and clarithromycin treatment for Helicobacter pylori eradication: the HYPER Study. Gut. 2007;56:475-479. [PMID: 17028126 DOI: 10.1136/gut.2006.102269] [Cited by in Crossref: 59] [Cited by in F6Publishing: 57] [Article Influence: 3.7] [Reference Citation Analysis]
78 Ibrahim MA, Sallem OW, Abdelhassib MR, Eldahshan OA. Potentiation of anti-Helicobacter pylori activity of clarithromycin by Pelargonium graveolens oil. Arab J Gastroenterol 2021;22:224-8. [PMID: 34531132 DOI: 10.1016/j.ajg.2021.05.016] [Reference Citation Analysis]
79 Wylie MR, Windham IH, Blum FC, Wu H, Merrell DS. In vitro antibacterial activity of nimbolide against Helicobacter pylori. J Ethnopharmacol 2021;:114828. [PMID: 34763046 DOI: 10.1016/j.jep.2021.114828] [Reference Citation Analysis]
80 Sue S, Ogushi M, Arima I, Kuwashima H, Nakao S, Naito M, Komatsu K, Kaneko H, Tamura T, Sasaki T, Kondo M, Shibata W, Maeda S. Vonoprazan- vs proton-pump inhibitor-based first-line 7-day triple therapy for clarithromycin-susceptible Helicobacter pylori: A multicenter, prospective, randomized trial. Helicobacter. 2018;23:e12456. [PMID: 29271026 DOI: 10.1111/hel.12456] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
81 Moon JY, Kim GH, You HS, Lee BE, Ryu DY, Cheong JH, Jung JI, Jeong JH, Song CS, Song GA. Levofloxacin, Metronidazole, and Lansoprazole Triple Therapy Compared to Quadruple Therapy as a Second-Line Treatment of Helicobacter pylori Infection in Korea. Gut Liver. 2013;7:406-410. [PMID: 23898379 DOI: 10.5009/gnl.2013.7.4.406] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
82 Ramas M, Donday MG, McNicholl AG, Gisbert JP. Efficacy and safety of rifaximin associated with standard triple therapy (omeprazole, clarithromycin and amoxicillin) for H. pylori eradication: A phase IV pilot clinical trial. Gastroenterol Hepatol 2017;40:658-62. [PMID: 28780968 DOI: 10.1016/j.gastrohep.2017.05.017] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
83 Gambaro C, Bilardi C, Dulbecco P, Iiritano E, Zentilin P, Mansia C, Usai P, Vigneri S, Savarino V. Comparable Helicobacter pylori eradication rates obtained with 4- and 7-day rabeprazole-based triple therapy: a preliminary study. Dig Liver Dis. 2003;35:763-767. [PMID: 14674665 DOI: 10.1016/s1590-8658(03)00458-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
84 Gisbert JP, Calvet X, Bermejo F, Boixeda D, Bory F, Bujanda L, Castro-Fernández M, Dominguez-Muñoz E, Elizalde JI, Forné M, Gené E, Gomollón F, Lanas Á, Martín de Argila C, McNicholl AG, Mearin F, Molina-Infante J, Montoro M, Pajares JM, Pérez-Aisa A, Pérez-Trallero E, Sánchez-Delgado J. [III Spanish Consensus Conference on Helicobacter pylori infection]. Gastroenterol Hepatol 2013;36:340-74. [PMID: 23601856 DOI: 10.1016/j.gastrohep.2013.01.011] [Cited by in Crossref: 49] [Cited by in F6Publishing: 26] [Article Influence: 5.4] [Reference Citation Analysis]
85 Zhang X, Jiang A, Qi B, Yu H, Xiong Y, Zhou G, Qin M, Dou J, Wang J. Secretion expression of human neutrophil peptide 1 (HNP1) in Pichia pastoris and its functional analysis against antibiotic-resistant Helicobacter pylori. Appl Microbiol Biotechnol 2018;102:4817-27. [DOI: 10.1007/s00253-018-8982-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
86 Calvet X. Helicobacter pylori infection: treatment options. Digestion. 2006;73 Suppl 1:119-128. [PMID: 16498260 DOI: 10.1159/000089787] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
87 Kim JS, Kim BW, Ham JH, Park HW, Kim YK, Lee MY, Ji JS, Lee BI, Choi H. Sequential Therapy for Helicobacter pylori Infection in Korea: Systematic Review and Meta-Analysis. Gut Liver 2013;7:546-51. [PMID: 24073312 DOI: 10.5009/gnl.2013.7.5.546] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 3.3] [Reference Citation Analysis]
88 Bang CS, Baik GH. Attempts to enhance the eradication rate of Helicobacter pylori infection. World J Gastroenterol 2014; 20(18): 5252-5262 [PMID: 24833855 DOI: 10.3748/wjg.v20.i18.5252] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
89 Dutta AK, Phull PS. Treatment of Helicobacter pylori infection in the presence of penicillin allergy. World J Gastroenterol 2021; 27(44): 7661-7668 [PMID: 34908805 DOI: 10.3748/wjg.v27.i44.7661] [Reference Citation Analysis]
90 Gisbert JP, Calvet X. Review article: the effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough. Aliment Pharmacol Ther. 2011;34:1255-1268. [PMID: 22017749 DOI: 10.1111/j.1365-2036.2011.04887.x] [Cited by in Crossref: 79] [Cited by in F6Publishing: 71] [Article Influence: 7.2] [Reference Citation Analysis]
91 Serin E, Gumurdulu Y, Ozer B, Kayaselcuk F, Yilmaz U, Kocak R. Impact of Helicobacter pylori on the Development of Vitamin B12 Deficiency in the Absence of Gastric Atrophy. Helicobacter 2002;7:337-41. [DOI: 10.1046/j.1523-5378.2002.00106.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 42] [Article Influence: 2.1] [Reference Citation Analysis]
92 Gisbert JP, Khorrami S, Calvet X, Pajares JM. Systematic review: Rabeprazole-based therapies in Helicobacter pylori eradication. Aliment Pharmacol Ther. 2003;17:751-764. [PMID: 12641497 DOI: 10.1046/j.1365-2036.2003.01450.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 1.4] [Reference Citation Analysis]
93 Zhang X, Jiang A, Wang G, Yu H, Qi B, Xiong Y, Zhou G, Qin M, Dou J, Wang J. Fusion expression of the PGLa-AM1 with native structure and evaluation of its anti-Helicobacter pylori activity. Appl Microbiol Biotechnol 2017;101:5667-75. [DOI: 10.1007/s00253-017-8302-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
94 Buzás GM, Györffy H, Széles I, Szentmihályi A. Second-line and third-line trial for helicobacter pylori infection in patients with duodenal ulcers: A prospective, crossover, controlled study. Curr Ther Res Clin Exp 2004;65:13-25. [PMID: 24764586 DOI: 10.1016/S0011-393X(04)90001-X] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
95 Assem M, El Azab G, Rasheed MA, Abdelfatah M, Shastery M. Efficacy and safety of Levofloxacin, Clarithromycin and Esomeprazol as first line triple therapy for Helicobacter pylori eradication in Middle East. Prospective, randomized, blind, comparative, multicenter study. European Journal of Internal Medicine 2010;21:310-4. [DOI: 10.1016/j.ejim.2010.05.011] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 1.6] [Reference Citation Analysis]
96 Gisbert JP, Pajares JM. Helicobacter pylori "rescue" therapy after failure of two eradication treatments. Helicobacter. 2005;10:363-372. [PMID: 16181345 DOI: 10.1111/j.1523-5378.2005.00324.x] [Cited by in Crossref: 78] [Cited by in F6Publishing: 70] [Article Influence: 4.6] [Reference Citation Analysis]
97 Sharara AI, Chaar HF, Racoubian E, Moukhachen O, Barada KA, Mourad FH, Araj GF. Efficacy of two rabeprazole/gatifloxacin-based triple therapies for Helicobacter pylori infection. Helicobacter. 2004;9:255-261. [PMID: 15165262 DOI: 10.1111/j.1083-4389.2004.00220.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.0] [Reference Citation Analysis]
98 Fennerty MB, Magaret N, Dalros L, Faigel D, Lieberman D, Shaw M. Outcomes of Helicobacter pylori treatment in community practice and impact of therapeutic effectiveness information on physician behaviour. Aliment Pharmacol Ther 2001;15:1453-8. [PMID: 11552918 DOI: 10.1046/j.1365-2036.2001.01049.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
99 Veldhuyzen Van Zanten S, Machado S, Lee J. One-week triple therapy with esomeprazole, clarithromycin and metronidazole provides effective eradication of Helicobacter pylori infection. Aliment Pharmacol Ther. 2003;17:1381-1387. [PMID: 12786632 DOI: 10.1046/j.1365-2036.2003.01554.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 27] [Article Influence: 1.2] [Reference Citation Analysis]
100 Zuckerman JM. Macrolides and ketolides: azithromycin, clarithromycin, telithromycin. Infect Dis Clin North Am 2004;18:621-49, xi-. [PMID: 15308279 DOI: 10.1016/j.idc.2004.04.010] [Cited by in Crossref: 122] [Cited by in F6Publishing: 96] [Article Influence: 6.8] [Reference Citation Analysis]
101 Buzás GM, Széles I. Interpretation of the 13C-urea breath test in the choice of second- and third-line eradication of Helicobacter pylori infection. J Gastroenterol 2008;43:108-14. [PMID: 18306984 DOI: 10.1007/s00535-007-2135-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
102 Olokoba AB, Obateru OA, Bojuwoye MO. Helicobacter pylori eradication therapy: A review of current trends. Niger Med J. 2013;54:1-4. [PMID: 23661891 DOI: 10.4103/0300-1652.108884] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
103 Salehi B, Sharopov F, Martorell M, Rajkovic J, Ademiluyi AO, Sharifi-Rad M, Fokou PVT, Martins N, Iriti M, Sharifi-Rad J. Phytochemicals in Helicobacter pylori Infections: What Are We Doing Now? Int J Mol Sci 2018;19:E2361. [PMID: 30103451 DOI: 10.3390/ijms19082361] [Cited by in Crossref: 50] [Cited by in F6Publishing: 45] [Article Influence: 12.5] [Reference Citation Analysis]
104 Gisbert JP, Khorrami S, Calvet X, Pajares JM. Pantoprazole based therapies in Helicobacter pylori eradication: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2004;16:89-99. [PMID: 15095858 DOI: 10.1097/00042737-200401000-00014] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.2] [Reference Citation Analysis]
105 Nagaraja V, Eslick GD. Evidence-based assessment of proton-pump inhibitors in Helicobacter pylori eradication: A systematic review. World J Gastroenterol 2014; 20(40): 14527-14536 [PMID: 25356018 DOI: 10.3748/wjg.v20.i40.14527] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
106 Scarpignato C. Towards the ideal regimen for Helicobacter pylori eradication: the search continues. Dig Liver Dis. 2004;36:243-247. [PMID: 15115334 DOI: 10.1016/j.dld.2004.01.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
107 Shea BJ, Bouter LM, Peterson J, Boers M, Andersson N, Ortiz Z, Ramsay T, Bai A, Shukla VK, Grimshaw JM. External validation of a measurement tool to assess systematic reviews (AMSTAR). PLoS One. 2007;2:e1350. [PMID: 18159233 DOI: 10.1371/journal.pone.0001350] [Cited by in Crossref: 340] [Cited by in F6Publishing: 321] [Article Influence: 22.7] [Reference Citation Analysis]
108 Hawkey CJ, Atherton JC, Treichel HC, Thjodleifsson B, Ravic M. Safety and efficacy of 7-day rabeprazole- and omeprazole-based triple therapy regimens for the eradication of Helicobacter pylori in patients with documented peptic ulcer disease: PROTON PUMP INHIBITOR-BASED TRIPLE THERAPY. Alimentary Pharmacology & Therapeutics 2003;17:1065-74. [DOI: 10.1046/j.1365-2036.2003.01492.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 1.4] [Reference Citation Analysis]
109 Lauener FN, Imkamp F, Lehours P, Buissonnière A, Benejat L, Zbinden R, Keller PM, Wagner K. Genetic Determinants and Prediction of Antibiotic Resistance Phenotypes in Helicobacter pylori. J Clin Med 2019;8:E53. [PMID: 30621024 DOI: 10.3390/jcm8010053] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 12.3] [Reference Citation Analysis]
110 Goddard AF, Logan RP. Diagnostic methods for Helicobacter pylori detection and eradication. Br J Clin Pharmacol 2003;56:273-83. [PMID: 12919175 DOI: 10.1046/j.1365-2125.2003.01941.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
111 Calvet X, Gené E. Erradicar Helicobacter pylori.¿Terapia triple o cuádruple?, ¿corta o larga? Gastroenterología y Hepatología 2003;26:325-9. [DOI: 10.1016/s0210-5705(03)70366-5] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
112 Gisbert JP, Gisbert JL, Marcos S, Olivares D, Pajares JM. Helicobacter pylori first-line treatment and rescue options in patients allergic to penicillin. Aliment Pharmacol Ther 2005;22:1041-6. [DOI: 10.1111/j.1365-2036.2005.02687.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 2.2] [Reference Citation Analysis]
113 Gisbert JP, Molina-Infante J, Amador J, Bermejo F, Bujanda L, Calvet X, Castro-Fernández M, Cuadrado-Lavín A, Elizalde JI, Gene E, Gomollón F, Lanas Á, Martín de Argila C, Mearin F, Montoro M, Pérez-Aisa Á, Pérez-Trallero E, McNicholl AG. IV Spanish Consensus Conference on Helicobacter pylori infection treatment. Gastroenterol Hepatol 2016;39:697-721. [PMID: 27342080 DOI: 10.1016/j.gastrohep.2016.05.003] [Cited by in Crossref: 72] [Cited by in F6Publishing: 46] [Article Influence: 12.0] [Reference Citation Analysis]
114 Buzás GM, Józan J. First-line eradication of H pylori infection in Europe: A meta-analysis based on congress abstracts, 1997-2004. World J Gastroenterol 2006; 12(33): 5311-5319 [PMID: 16981260 DOI: 10.3748/wjg.v12.i33.5311] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
115 Ogura K, Mitsuno Y, Maeda S, Hirata Y, Yanai A, Shibata W, Ohmae T, Yoshida H, Kawabe T, Omata M. Efficacy and Safety of Faropenem in Eradication Therapy of Helicobacter pylori: Faropenem against Helicobacter pylori. Helicobacter 2007;12:618-22. [DOI: 10.1111/j.1523-5378.2007.00551.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
116 Scarpignato C. Antisecretory drugs, Helicobacter pylori infection and symptom relief in GORD: Still an unexplored triangle. Digestive and Liver Disease 2005;37:468-74. [DOI: 10.1016/j.dld.2005.03.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
117 Manes G, Pieramico O, Perri F, Vaira D, Giardullo N, Romano M, Nardone G, Balzano A. Twice-daily standard dose of omeprazole achieves the necessary level of acid inhibition for Helicobacter pylori eradication. A randomized controlled trial using standard and double doses of omeprazole in triple therapy. Dig Dis Sci. 2005;50:443-448. [PMID: 15810623 DOI: 10.1007/s10620-005-2455-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
118 Thung I, Aramin H, Vavinskaya V, Gupta S, Park JY, Crowe SE, Valasek MA. Review article: the global emergence of Helicobacter pylori antibiotic resistance. Aliment Pharmacol Ther. 2016;43:514-533. [PMID: 26694080 DOI: 10.1111/apt.13497] [Cited by in Crossref: 310] [Cited by in F6Publishing: 288] [Article Influence: 44.3] [Reference Citation Analysis]
119 Scarpignato C, Pelosini I, Di Mario F. Acid suppression therapy: Where do we go from here? Dig Dis. 2006;24:11-46. [PMID: 16699262 DOI: 10.1159/000091298] [Cited by in Crossref: 61] [Cited by in F6Publishing: 55] [Article Influence: 3.8] [Reference Citation Analysis]
120 Gisbert JP, Molina-Infante J, Marin AC, Vinagre G, Barrio J, McNicholl AG. Second-line rescue triple therapy with levofloxacin after failure of non-bismuth quadruple "sequential" or "concomitant" treatment to eradicate H. pylori infection. Scand J Gastroenterol. 2013;48:652-656. [PMID: 23556551 DOI: 10.3109/00365521.2013.786132] [Cited by in Crossref: 18] [Cited by in F6Publishing: 26] [Article Influence: 2.0] [Reference Citation Analysis]
121 Gisbert JP, Pajares JM. Treatment of helicobacter pylori eradication failures. Curr Treat Options Gastro 2003;6:147-56. [DOI: 10.1007/s11938-003-0015-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]